

Published in final edited form as:

Wiley Interdiscip Rev Dev Biol. 2012 ; 1(3): 315–327. doi:10.1002/wdev.30.

Making Skeletal Muscle from Progenitor and Stem Cells: Development versus Regeneration

Chen-Ming Fan, Lydia Li², Michelle E. Rozo², and Christoph Lepper²

Department of Embryology, Carnegie Institution of Washington, 3520 San Martin Drive, Baltimore, MD 21218

Abstract

For locomotion, vertebrate animals use the force generated by contractile skeletal muscles. These muscles form an actin/myosin-based bio-machinery that is attached to skeletal elements to effect body movement and maintain posture. The mechanics, physiology, and homeostasis of skeletal muscles in normal and disease states are of significant clinical interest. How muscles originate from progenitors during embryogenesis has attracted considerable attention from developmental biologists. How skeletal muscles regenerate and repair themselves after injury by the use of stem cells is an important process to maintain muscle homeostasis throughout lifetime. In recent years, much progress has been made towards uncovering the origins of myogenic progenitors and stem cells as well as the regulation of these cells during development and regeneration.

Introduction

In humans, more than 600 skeletal muscle groups are anatomically defined. Despite their complexity in shape and function, each muscle group is made up of hundreds to thousands of fundamental structural units called myofibers. The myofiber is unique in its constitution as it is a multi-nucleated syncytium containing tens to hundreds of nuclei resulting from cellular fusion of differentiated single muscle cells, the myocytes. Progenitors that give rise to these differentiated myocytes are a subject of this review. Stem cells that repair damaged myofibers or regenerate new myofibers after trauma in the adult are also evaluated. In particular, we contrast similarities and differences of cellular and molecular events that orchestrate muscle development and regeneration.

I. Cell origin and lineage of myogenic progenitors and stem cells

The embryonic origin of skeletal muscles and their progenitors—The entire trunk and limb skeletal muscles arise from a transient embryonic mesodermal structure called the somite (Fig. 1). Somites are segmented mesodermal units flanking both sides of the spinal cord that were first visualized by Marcello Malpighi in the chick embryo¹. It is therefore fitting that chick embryos have been a primary experimental system for investigating skeletal muscle development since the 1970s². In particular, chick-quail chimera experiments³, in which surgically combined host and donor cells can be distinguished by nucleolar morphology or quail-specific antigen, were performed to demonstrate a somitic origin of the limb musculature^{4,5}. The dorsal epithelial portion of the somite, the dermomyotome, contains the myogenic progenitors⁶. Furthermore, limb and ventral body wall muscles only come from the ‘lateral’ half of the somite, while the dorsal axial muscles derive from the ‘medial’ half⁷. Focal labeling of somitic cells with fluorescent

Correspondence to: Chen-Ming Fan.

²These authors contributed equally

dyes was also used to evaluate the morphology of emerging myogenic cells^{8,9}. Live imaging of such labeled cells revealed that cells near the medial and lateral borders (or ‘lips’) of the dermomyotome, represent the primary wave of myogenic cells¹⁰. The myogenic contribution of the central portion of the dermomyotome was not addressed in these studies.

En1 is specifically expressed in the central dermomyotome of the mouse. Using loxP-recombination-based LacZ reporter expression for cell marking/tracing via *En1* gene-directed *Cre* (*En1-Cre*) activity, Atit et al.¹¹ showed that marked central dermomyotome cells (at embryonic day 9.5; E9.5) become a triangular domain underneath the dermomyotome a day later (at E10.5). Descendant cells become incorporated not only into dorsal trunk muscles, but also interscapular brown fat and dorsal dermis at E16.5¹¹ (Table 1). A chick-quail chimera study has long since determined that embryonic muscles and their progenitors have the same somitic origin¹². A recent revisit of this issue agrees with trunk muscle and dermis fates deriving from central dermomyotome cells¹³, though chick has no brown fat for comparison. Gros et al.¹³ further showed by live imaging that GFP-expressing central dermomyotome cells divided vertically (relative to the epithelial plane) with one daughter cell moving inward, explaining the triangular domain observed in *En1-Cre* marked somites. Using reporter gene knock-in alleles of two dermomyotome-expressing genes, *Pax3* and *Pax7* (encoding related transcription factors), Relaix et al.¹⁴ concluded that the vertically dividing cells were indeed *Pax3*⁺*Pax7*⁺ central dermomyotome cells that give rise to a new population of inner cells. As *Pax3*;*Pax7* double mutants failed to generate additional myogenic cells after the primary wave of myogenesis, *Pax3*⁺*Pax7*⁺ cells represent the secondary progenitors for continuous expansion of muscle mass (Fig. 1).

Central dermomyotome cells do not contribute to ventral body wall or limb muscles. These two populations originate from the lateral half of the somite⁷, presumably the lateral dermomyotome. This region expresses high levels of *Pax3* and mice mutant for *Pax3* alone lack these muscles¹⁵. Because *Pax3* is also expressed in the presomitic mesoderm^{16,17}, *Pax3*-Cre-mediated lineage tracing precludes assignment of limb and ventral body wall muscle progenitors specifically to the lateral dermomyotome¹⁸ (Table 1). A transgenic line called *M-Cre* was used to help define the lateral dermomyotome as a source of limb muscle progenitors¹⁸. However, constitutive Cre mediated lineage-tracing marks all cells expressing Cre ‘at any one time’ prior to the assay time point, thus negating temporal specificity. As a gene often possesses a dynamic expression pattern, analysis of constitutive Cre-based lineage tracing must include all expression patterns prior to the assay time point for accurate interpretation.

The tamoxifen inducible forms of Cre, the Cre-ER fusion and its successive improved versions Cre-ER^T and Cre-ER^{T2}, offer an opportunity for temporally controlled cell marking¹⁹. Using a *Pax7-Cre-ER^{T2}* allele for inducible lineage tracing, it was found that *Pax7*-expressing cells marked at different time points contribute to different sets of cell fates and muscle groups²⁰ (Table 1). When central dermomyotome cells were marked at E9.5, they contribute to the three fates revealed by the *En1-Cre* and *En1-Cre-ER^T* study¹¹. *Pax7*⁺ cells marked at E10.5 contribute to ventral and proximal forelimb muscles, and brown fat, but less so to dermis. E11.5 marked cells do not contribute to dermis, but they can be traced to distal fore- and hind-limb muscles and some brown fat. By E12.5, *Pax7*-descendant cells become restricted to the myogenic lineage and are found even in the most distal limb muscles. How three fates become segregated from a simple epithelium (the dermomyotome) and how *Pax7*⁺ cells become fate restricted to the myogenic lineage are fundamental cell fate determination issues that have yet to be experimentally explored.

Myogenic specification and differentiation—Myogenic differentiation has been extensively studied and reviewed^{21,22}. Following is a brief summary. Cloning of *MyoD*

changed the landscape of the myogenic field²³. Forced expression of this transcription factor can convert various cultured cell types to the myogenic fate, earning its reputation as the master regulator of myogenesis. *MyoD* has three related family members, *Myf5*, *Myf6* (also called *Mrf4*), and *Myogenin*²⁴. Their expression is largely restricted to the myogenic lineage. *MyoD* and *Myf5* expression prefigures the differentiated myocytes and defines the myogenic domain (Fig. 1). *Myogenin* is turned on in the myocytes prior to their fusion into myofibers. *Myf6* expression is the last to be detected. *Myf5* mutants lack the initial myotome, but this defect is compensated and mutants eventually develop with negligible muscle defects²⁵. Single mutants for *MyoD* or *Myf6* are also viable with no severe muscle defects at birth^{26,27}. However, *Myf5/Myf6/MyoD* triple mutants have drastically reduced embryonic muscles²⁸. *Myogenin* mutants have no defects in myogenic specification and differentiation, but a defect in myocyte fusion in the trunk and limbs²⁹. *MyoD;Myf6* double mutants are also defective in myocyte fusion³⁰. Importantly, *MyoD;Myf6;Myogenin* triple mutants are devoid of any myocyte fusion, despite normal *Myf5* expression³⁰. It therefore appears that *Myf5* acts primarily at the early step of specification and *Myogenin* at the late step of myocyte fusion, while *MyoD* and/or *Myf6* can participate in both steps in a semi-redundant fashion. These four genes' function and regulation are complex and not necessarily agreed upon by all investigators in the field. Nevertheless, embryonic myogenesis involves intricate interplays between these myogenic regulatory factors (MRFs).

Surprisingly, *Myf5-Cre* marked cells contribute to brown fat³¹, in addition to muscles and committed myogenic progenitors³², suggesting that its expression does not commit cells to myogenic differentiation (Table 1). However, the *Myf5-Cre* knock-in construct used a constitutive Cre and an exogenous polyA signal, which precludes endogenous 3'UTR usage and miRNA regulation. It is therefore not completely clear whether there was 'aberrant' or 'unintended' expression of Cre in an earlier progenitor stage. For example, *Myf5-Cre* is expressed in the presomitic mesoderm, where Myf5 protein is not detected³³. Therefore, not surprisingly, *Myf5-Cre* also directs lineage labeling in cartilage and dermis in this study. If a subpopulation of *Myf5*⁺ cells is indeed multi-potential, it will be important to determine their temporal and spatial distribution. By contrast, *MyoD-Cre*³⁴ and *Myogenin-Cre*³³ have thus far only been reported to mark the myogenic lineage (Table 1).

Muscle progenitors in the peri-natal period—The *Pax7*⁺ cell source represents a major contributor to myofibers during the first 3 weeks of birth based on temporally controlled labeling and tracing of hind limb muscles using the *Pax7-Cre-ERT2* allele³⁵. In other muscle groups, notably most trunk and the diaphragm muscles, myogenic progenitors also express *Pax3*³⁶. Whether all *Pax7*⁺ myogenic progenitor cells detected in the perinatal period are descendants of embryonic *Pax7*⁺ cells has not been conclusively determined as tamoxifen-induced labeling efficiency in the embryo is low²⁰. There is a recent report that peri-natal *Pax7*⁺ cells can arise from *PW1*⁺*Pax7*⁻ muscle interstitial cells³⁷. Using CD34 and Sca1 surface antigens for fluorescent-activated cell sorting (FACS), the investigators described ~56% of the CD34⁺Sca1^{high} fraction expresses *PW1* but not *Pax7*, and these cells can generate muscles and *Pax7*⁺ cells after transplantation into adult animals. Because these cells never express *Pax3* during embryogenesis (not marked in *Pax3-Cre* mice), they are presumably not of somitic origin. However, at least some embryonically and perinatally marked *Pax7*⁺ cells can directly contribute to adult muscle stem cells^{20,35}. The relative contributions of embryonic versus peri-natal *de novo* *Pax7*⁺ cells to muscle fiber formation and adult muscle stem cells are currently unclear.

Although the *Pax7* mutant has no discernable embryonic muscle defect (unless combined with the *Pax3* mutation), *Pax7* is essential for perinatal myogenesis. *Pax7* mutants are born with a normal number of cells actively transcribing the *Pax7* locus in hind limb muscles (scored by knock-in reporter expression or by *Pax7-Cre-ERT2*-mediated reporter

expression³⁵). This number declines in ensuing weeks; consequently, surviving mutant adults have barely any satellite cell and are extremely compromised in injury induced muscle regeneration^{38,39}. Mitotic defect³⁸, cell death⁴⁰, and reduced myogenic potential³⁹ have been implicated in the loss of satellite cells. Inducible lineage tracing of mutant cells showed that they do incorporate into myofibers more readily and over a longer period relative to control cells³⁵. Thus, *Pax7* likely maintains the progenitor pool size by counterbalancing the tendency to differentiate. How *Pax7* acts, how its expression is regulated, and how the number of Pax7⁺ cells is controlled during this period are critical questions pertaining to the establishment of a normal pool of muscle stem cells for use throughout the active life of a vertebrate animal.

As Pax7⁺ cells continuously incorporate into myofibers during the perinatal period, one predicts that their differentiation depends on the *MyoD* gene family. However, as mentioned above, *Myf5*, *MyoD*, and *Myf6* single mutants can develop to adulthood with relatively normal skeletal muscles, presumably due to redundancy between these genes. Intriguingly, *MyoD-Cre* was shown to direct lineage labeling of perinatal Pax7⁺ muscle progenitors at a high rate³⁴. *Myf5-Cre* also directs marking of postnatal Pax7⁺ cells³². Since neither protein has been detected in muscle stem cells, these knock-in *Cre* genes must be transcribed in muscle progenitor/stem cells sometime in the history of their making. Whether these two genes play a redundant role in this process is unknown. Systematic combinations of conditional gene inactivation among *Myf5*, *MyoD*, *Mrf4*, and *Myogenin* during the perinatal period will help to define their roles, relative to those defined in embryogenesis by the respective germ line mutants.

Adult myogenic stem cells in injury-induced skeletal muscle regeneration—In adulthood, skeletal muscle possesses a tremendous capacity to repair itself after extensive injury, which is exemplified by full tissue restoration after mincing of an entire skeletal muscle⁴¹. The tissue's regenerative potential is maintained over up to 50 toxin-induced injury/regeneration cycles⁴². Such regenerative capacity has been largely attributed to muscle stem cells endogenous to the skeletal muscle. One such cell type is the satellite cell, which was first identified by Alexander Mauro exactly fifty years ago using transmission electron microscopy (TEM) performed on frog tibialis anticus (i.e. tibialis anterior) muscle⁴³. These cells are named after their physical location: attached to the sarcolemma and beneath the basal lamina 'orbiting' the muscle fiber. In the same year, *in vitro* culture experiments with myoblasts obtained by enzymatic digestion of skeletal muscle tissue established that mononucleated muscle progenitor cells could give rise to multi-nucleated myofibers via fusion^{44,45}. Whether *in vitro* isolated myoblasts corresponded to TEM-defined satellite cells *in vivo* was not certain at the time. Years later, elegant transplantation experiments of muscles, in which satellite cell nuclei pulse-labeled with tritiated thymidine were chased into myonuclei, demonstrated that satellite cells could proliferate and potentially differentiate into muscle fibers after transplantation-induced injury⁴⁶. Further progress in the satellite cell field was impeded in large part due to a lack of satellite cell specific molecular markers and consequently, satellite cell research was limited to laborious ultra-anatomical studies by TEM.

Identification of *Pax7* being specifically expressed in skeletal myofiber associated cells that resemble satellite cells has greatly accelerated research in the field⁴⁷. An EM study of the frog leg muscle has detected Pax7 immuno-reactivity in the satellite cell⁴⁸. Similarly, we found Pax7 immuno-reactivity and β -gal enzymatic activity driven by *Pax7-Cre-ER^{T2};LacZ* reporter in satellite cells of mouse tibialis anterior muscles by TEM (Fig. 2). These findings provided evidence that Pax7⁺ cells are bona fide satellite cells as described by Alexander Mauro. However, Pax7 is not the only marker used for identifying satellite cells. For example, the *Myf5^{nLacZ}* knock-in allele directs β -gal activity in a large proportion of

satellite cells. Transplantation of single muscle fibers along with their myofiber-associated cells from *Myf5^{nLacZ}* mice into immuno-compromised and irradiated dystrophic muscles gave rise to hundreds of genetically marked myonuclei and satellite cells⁴⁹. Montarras et al.³⁶ obtained similar results via transplantation of Pax3⁺ cells isolated by FACS on the basis of fluorescent reporter gene expression from the *Pax3* locus. More recently, it has become possible to isolate adult muscle progenitor cells via FACS using a combination of positive and negative selections of cell surface markers^{32,50,51}. When transplanted in bulk into dystrophic muscles of immune-deficient mice, these various populations of cells proficiently contributed myonuclei to myofibers, as well as satellite cells to the host muscle fiber niches. Importantly, Sacco et al.⁵⁰ found all cells sorted by CD45⁻Sca1⁻CD34⁺β1integrin⁺ criteria positive for *Pax7* by single cell RT-PCR assay, and transplantation of such single cells results in the generation of new muscles and stem cells, fulfilling the 'gold standard' for demonstrating their stemness⁵². It remains to be determined whether all or only some *in vitro* defined transplantation competent muscle stem cell populations contain Pax7⁺ cells.

The above evidence for various sources of muscle stem cells is based upon *in vitro* isolation followed by transplantation, a long time tradition for studying stem cells. Using the *Pax7-Cre-ER^{T2}* mice for adult-specific cell marking and lineage tracing, Lepper et al.³⁵ provided direct *in vivo* evidence for Pax7⁺ satellite cells being the major source of muscle stem cells: after toxin-induced injury to the tibialis anterior muscle, lineage-labeled Pax7⁺ descendant cells robustly contributed to all regenerative myofibers and self-renewed to replenish the pool of quiescent satellite cells³⁵. While this unequivocally demonstrates that Pax7⁺ cells are a major source of muscle stem cells in acute injury induced muscle regeneration, it will be important to determine the role of these cells in other physiological contexts, including long-term skeletal muscle tissue maintenance, exercise-induced muscle growth, and muscle wasting diseases. Moreover, a critical question concerns whether Pax7⁺ cells are the exclusive muscle stem cell source. As new myofibers form as a syncytium by fusion of multiple myocytes, lineage marking of the Pax7⁺ cell population alone cannot be used to exclude the input from other cell sources within the same myofiber due to diffusion of the lineage tracer. Indeed, numerous transplantation-based studies have reported several different Pax7⁻ cell types contributing to both myofibers as well as the satellite cell compartment⁵³. To determine the physiological relevance of these clinically relevant cells for curing muscle degenerative diseases, it will be important to ascertain the role of them via direct lineage-tracing and/or genetic cell ablation of Pax7⁺ satellite cells to reveal if there is any remaining capacity for adult myogenesis.

Quite unexpectedly, tamoxifen-induced adult-specific inactivation of *Pax7* alone (via *Pax7-Cre-ER^{T2}* allele³⁵) or *Pax3* and *Pax7* together (via a widely expressed *Cre-ER^T* allele⁵⁴) does not cause an obvious defect in injury-induced muscle regeneration. The conditional mutant *Pax7* cell is not only able to regenerate myofibers effectively, but also proliferate, re-occupy the architectural satellite cell niche, and support an additional round of muscle regeneration. One could not help asking what is the function of *Pax7* in adult satellite cells? Whether other transcription factors compensate for or replace its role in adult satellite cell function is an open question. Along the same line of comparing gene function at different stages of myogenesis, the *MyoD* mutant develops with embryonic muscles relatively normally, but in adulthood muscle regeneration is compromised due to defects in myoblast proliferation and differentiation^{55,56}. *Myf5* mutants also develop muscles normally, but are defective in muscle regeneration due to compromised myoblast proliferation^{57,58}. Conversely, while *Myogenin* is required for embryonic myocyte fusion, this function of *Myogenin* is dispensable post-natally⁵⁹. Instead Myogenin controls a distinct transcriptional program⁵⁹, in particular the response to denervation-induced muscle atrophy⁶⁰. The

significance of such temporal switching of myogenic gene functions may lie in the fundamental differences between development and regeneration.

II. Signaling during myogenesis

Myogenic induction by Wnt proteins—In the embryo, the spinal cord and surface ectoderm surrounding the somite are necessary and sufficient for inducing myogenesis^{17,61-63}. Several *Wnt* genes are expressed in these two tissues. Co-cultures of presomitic cells and cells producing selective Wnt proteins induce expression of *Pax3* and *Pax7*⁶⁴, as well as *Myf5* and *MyoD*^{65,66}. In accordance, *Wnt1;Wnt3a* (both normally expressed in the dorsal spinal cord) double mutant embryos have reduced expression of *Pax3* and *Myf5* in the medial dermomyotome⁶⁷. The myogenic inducing potential of Wnt genes expressed by the surface ectoderm has not been tested genetically. *In vitro* pharmacological studies suggest that Wnts activate the G α - adenylyl cyclase - protein kinase A signaling cascade to phosphorylate the transcription factor CREB, which in turn activates myogenic genes. Consistently, both germ line inactivation of *Creb* and dominant negative *Creb* over-expression in the somite lead to severely reduced expression of *Pax3*, *Myf5*, and *MyoD in vivo*⁶⁶. In addition, the PKC pathway, which can be activated via G α signaling, has also been implicated in myogenic induction by modulating Pax3 activity and *MyoD* expression⁶⁸.

The canonical Wnt/ β -catenin pathway also plays a role in myogenesis. Inactivation of β -catenin in presomitic mesoderm cells leads to disorganized somites due to segmentation defects⁶⁹, disallowing a firm conclusion about its role in the primary wave of myogenesis⁷⁰. *En1-Cre* directed β -catenin inactivation in the central dermomyotome leads to an increase in the domain of myogenic cells at the expense of dermal cells, indicating an inhibitory role of β -catenin during the secondary wave of myogenesis¹¹. By contrast, β -catenin inactivation by *Pax7-Cre* caused only a modest defect in muscle architecture, represented by a change in muscle fiber sub-type distribution⁷⁰. Since both *Pax7* and *En1* are expressed in the central dermomyotome, the discrepancies likely reflect different timing of expression and/or efficiency of Cre between the two alleles. Analysis of the role of β -catenin via gene inactivation is further complicated by an accompanying cell adhesion defect in mutant cells. Inactivation of *BCL9*, which regulates β -catenin's nuclear activity but not its adhesion function, should in principle eliminate this issue. Yet, conditional inactivation of *BCL9* by *Myf5-Cre*, causes no developmental defects⁷¹. The timing of *Myf5-Cre* activity and BCL9 protein perdurance may obscure a potential role of the canonical pathway in embryonic myogenesis.

The role of Wnt signaling in adult regenerative myogenesis is multifaceted (Fig. 3). A selective combination of Wnt5a, 5b, 7a, and 7b can convert muscle resident CD45⁺Sca1⁺ cells (i.e. the side-population cells) to express Pax7⁷², suggesting that CD45⁺Sca1⁺ cells are a source of *de novo* Pax7⁺ stem cells for muscle regeneration. Although these *Wnt* genes were originally reported to be up-regulated during regeneration⁷², subsequent re-evaluation did not substantiate such claim⁷³. Thus, the physiological significance of the side-population cells and whether their conversion to Pax7⁺ cells occurs *in vivo* are not yet known. On the other hand, FGF6 and FGFR4 are expressed during the early phase of the regenerative response^{73,74}, and both *Fgf6* and *Fgfr4* mutants display compromised muscle regeneration^{74,75}, supporting the importance of FGF signaling pathway for proficient muscle repair.

For symmetric division of Pax7⁺ muscle stem cells, Wnt7a has been shown to employ the planar cell polarity (PCP) pathway: *Wnt7a* gene delivery into muscles via electroporation causes increased muscle stem cell number, and consequently muscle hypertrophy, and the PCP component Vangl-2 is a likely effector mediating this function⁷⁶. Although β -catenin

nuclear localization has been documented in cultured proliferating myoblasts, it may act in the transit amplifying progenitors rather than in the self-renewing stem cells⁷⁷. β -catenin nuclear localization is also detected in differentiating myogenic cells⁷¹. Importantly, *BCL9* inactivation or pharmacological intervention of β -catenin activity *in vivo* caused delayed myogenic differentiation but did not disturb progenitor proliferation during regeneration, evidence that the canonical pathway participates in the differentiation step^{71,78}. Wnt3a has also been shown to employ the canonical pathway to accelerate myocyte fusion using the *in vitro* C2C12 myoblast model⁷⁹. As myocyte fusion immediately follows differentiation, separating Wnt/ β -catenin functions in these two steps in unsynchronized populations of cells may prove to be difficult.

Lastly, Wnt/ β -catenin pathway activation also induces muscle fibrosis and thus, is implicated in the decline of muscle function in aging. Gene delivery of *Wnt3a* via intramuscular electroporation leads to fibrotic accumulation⁷⁶. *In vitro*, recombinant Wnt3a causes direct conversion of myoblasts into fibroblasts⁷⁸. Importantly, a β -catenin transcriptional reporter is activated in aging but not in young muscles after injury, and depletion of Wnt proteins via soluble Frz receptors can rejuvenize aged myoblasts to prevent fibrogenesis⁷¹. While Wnt acts locally to divert aging muscle stem cells to the fibrogenic fate, TGF β 1 has been reported to be a candidate systemic factor that may attenuate muscle stem cell activation^{80,81} as serum levels of TGF β 1 increase in aging humans and mice⁸². Most of the above cited effects of Wnt and TGF β 1 in adult and aging muscle regeneration are primarily based on *in vitro* culture or *in vivo overexpression*, pharmacology and RNAi studies; the genetic evidence remains to be obtained.

Maintenance of myogenic progenitors and stem cells by Notch signaling—The Notch-Delta receptor-ligand mediated signaling pathway has been shown to be instrumental in the regulation of various progenitor/stem cells and their differentiated daughters, including the myogenic progenitor and their differentiating progeny. Delta like 1 (Dll-1) mutant embryos initially have a normal number of Pax3⁺ and Pax7⁺ cells; over time, these cells become diminished⁸³. Similarly, somitic conditional inactivation of RBP-J κ , a transcriptional mediator of Notch signaling, also leads to a gradual depletion of Pax7⁺ cells⁸⁴. Consequently, by mid- to late embryogenesis, both Dll-1 and conditional RBP-J κ mutants have much reduced musculature. These data reinforce the positive role of Notch signaling in controlling the myogenic progenitor pool size.

One prominent negative regulator of Notch signaling is Numb. Asymmetric distribution of Numb during cell division helps determine distinct developmental paths of daughter cells by affecting differential Notch activities⁸⁵. Curiously, forced expression of a Numb-GFP fusion protein in mouse embryos⁸⁶ resulted in an increased progenitor pool, seemingly contradicting the positive role for Notch signaling in progenitor maintenance. Because this particular *Numb-GFP* transgene did not cause down-regulation of Notch reporter expression, it is still unresolved how Numb acts in regulating embryonic muscle progenitor cell number. When Numb protein distribution was followed by *in vitro* live imaging of post-natal myoblasts, either isolated in bulk⁸⁷ or from dissociated myofibers⁸⁸, it was found to be distributed both asymmetrically and symmetrically during cell division. The proportion of asymmetrically segregated Numb in daughter cells declined over successive divisions, possibly reflecting the absence of *in vivo* regulators in culture. While Shinin et al.⁸⁸ proposed that Numb co-segregates with the progenitor, Conboy et al.⁸⁷ suggested that Numb associates with the differentiating daughter cell. As of yet, the precise role of Numb in the myogenic lineage is not resolved.

Without examining Numb localization, symmetric and asymmetric satellite cell divisions can be observed in cultured myofibers and their associated satellite cells isolated from

Myf5-Cre;YFP reporter mice³². In this experimental paradigm, YFP was used as an indicator for a sub-population of satellite cells at one point in time expressing *Myf5* ($Pax7^+YFP^+$), relative to those expressing only *Pax7* ($Pax7^+YFP^-$)³². Two types of cell division were found. Type 1, planar symmetric cell division (along the plane of the myofiber) resulted in the majority of daughter cells either both maintaining the $Pax7^+YFP^-$ stem cell fate or both displaying *Myf5* expression ($Pax7^+YFP^+$). Type 2, asymmetric division along the apical-basal plane mostly gave rise to cells with different fates: the cell that divided away from the basal lamina gained *Myf5* expression ($Pax7^+YFP^+$), while the basal sister stayed in the satellite cell compartment and did not express *Myf5* ($Pax7^+YFP^-$). Furthermore, the cell that remained basally displayed elevated levels of *Notch3* while the apical cell expressed the *Dll-1*, suggesting that activation of *Notch3* by *Dll-1* positively selects the basal cells to maintain the stem cell fate. However, in response to repetitive muscle injury, *Notch3*-deficient mice regenerated better and had more satellite cells than control animals, suggesting that *Notch3* is instead a negative regulator of the muscle stem cell pool⁸⁹. By contrast, over-expression of an intracellular domain of *Notch1* (NICD, an activated form of *Notch1*) increased proliferation of cultured myoblasts⁸⁷, supporting its positive role in stem cell expansion. It is interesting to note that while *Notch1* is expressed in nearly all satellite cells, *Notch3* is expressed only in a subset. One may therefore speculate that the Notch pathway serves to regulate the number of satellite cells through the balanced activity between *Notch1* (positive) and *Notch3* (negative). Whether different Delta like ligands are involved in mediating differential Notch activities is yet to be explored.

Although *Dll-1* expression is up-regulated in injured muscles of young adults⁸⁷, aging muscles lose the ability to activate *Dll-1* after injury and are compromised in the regenerative process⁸⁰. Pharmacological inhibition of Notch signaling can indeed block muscle regeneration in young adult mice, while forced activation of Notch signaling is sufficient to restore efficient muscle regeneration in old mice⁸⁰. These results provide strong support for the continuous participation of Notch signaling in the maintenance of the skeletal muscle stem cell activity throughout lifetime. For studying the aging process, gene over-expression or functional blocking reagents, rather than genetic means, are often used. As such, the nuances of differential roles between gene family members may be overlooked. Restricting knockouts of each Delta and Notch gene to the muscle progenitors versus their surrounding cells will help to delineate the specific role of each gene member.

III. Regeneration recapitulates development?

Studies of embryonic muscle development and the muscle regeneration have primarily been two distinct disciplines. It has been largely by inferential extensions that these processes were compared. From the above descriptions, it should be clear that in many cases, the molecular mechanisms that control adult muscle regeneration do not recapitulate those that control embryonic myogenesis. During skeletal muscle progenitor and stem cell expansion and maintenance, there is a progressive change of genetic requirements for *Pax3* and *Pax7*, to *Pax7* only, to neither, from embryo, to neonate, to adult, respectively. For muscle differentiation, there is also a temporal shift of genetic contributions among the *MRF* members, for example, the roles of *MyoD* and *Myf5* during embryonic muscle development versus adult muscle regeneration reviewed above. The most striking shift of function is exemplified by *Myogenin*, which is required for fusion of embryonic myocytes but dispensable for fusion of regenerating adult myocytes⁹⁰. Lastly, the Wnt/ β -catenin pathway also appears to act differently during embryonic myogenesis, adult muscle regeneration, and aging muscle fibrosis. The pathway that is thus far continuously required for maintaining embryonic muscle progenitors and adult muscle stem cells is Notch signaling. Yet, *Notch3* is only required for maintaining muscle stem cell pool size after repeated injuries, but not for regulating the embryonic myogenic progenitor pool. There are many other signaling and

transcriptional regulators of muscle development and regeneration that have only been examined in one context but not in the other, but they are not covered here due to space. A comprehensive evaluation of these regulators in both contexts will help to conceptualize the differences between these two processes. Because embryonic development relies on active progenitors cycling continuously but adult muscle stem cells are relatively quiescent in the absence of injury, these two processes are fundamentally distinct. In particular, the muscle regenerative process involves stem cell activation and a return to a homeostatic state in a chaotic inflammatory environment not seen during embryogenesis. Therefore, it is only reasonable that these adult stem cells utilize different strategies from those employed by embryonic progenitors to adapt to unpredictable circumstances such as injury-induced regeneration.

Acknowledgments

We thank Mike Sepanski for help with electron microscopy of the satellite cells. C.-F. Fan and C. Lepper are supported by an NIH grant (AR060042). L. Li and M. E. Rozo are supported by Carnegie Endowment.

References

1. Malpighi M. 1672
2. Sanders, EJ.; Lash, JW.; Ordahl, CP. Origin and Fate of Somites. IOS Press; 2001.
3. Le Douarin N, Barq G. Sur l'utilisation des cellules de la caille japonaise comme 'marqueurs biologiques' en embryologie expérimentale. C r hebd Séanc Acad Sei Paris D. 1969; 269:1543–1546.
4. Chevallier A, Kieny M, Mauger A. Limb-somite relationship:origin of the limb musculature. Embryol exp Morph. 1977; 41:245–258.
5. Christ B, Jacob HJ, Jacob M. Experimental analysis of the origin of the wing musculature in avian embryos. Anat Embryol. 1977; 150:171–186. [PubMed: 857700]
6. Christ B, Brand-Saberi B, Grim M, Wilting J. Local signalling in dermomyotomal cell type specification. Anat Embryol. 1992; 186:505–510. [PubMed: 1443658]
7. Ordahl CP, Le Douarin NM. Two myogenic lineages within the developing somite. Development (Cambridge, England). 1992; 114:339–353.
8. Kaehn K, Jacob HJ, Christ B, Hinrichsen K, Poelmann RE. The onset of myotome formation in the chick. Anatomy and embryology. 1988; 177:191–201. [PubMed: 2451450]
9. Denetclaw WF Jr, Christ B, Ordahl CP. Location and growth of epaxial myotome precursor cells. Development (Cambridge, England). 1997; 124:1601–1610.
10. Denetclaw WF Jr, Berdugo E, Venters SJ, Ordahl CP. Morphogenetic cell movements in the middle region of the dermomyotome dorsomedial lip associated with patterning and growth of the primary epaxial myotome. Development (Cambridge, England). 2001; 128:1745–1755.
11. Atit R, et al. Beta-catenin activation is necessary and sufficient to specify the dorsal dermal fate in the mouse. Developmental biology. 2006; 296:164–176. [PubMed: 16730693]
12. Armand O, Boutineau AM, Mauger A, Pautou MP, Kieny M. Origin of satellite cells in avian skeletal muscles. Arch Anat Microsc Morphol Exp. 1983; 72:163–181. [PubMed: 6651304]
13. Gros J, Manceau M, Thome V, Marcelle C. A common somitic origin for embryonic muscle progenitors and satellite cells. Nature. 2005; 435:954–958. [PubMed: 15843802]
14. Relaix F, Rocancourt D, Mansouri A, Buckingham M. A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. Nature. 2005; 435:948–953. [PubMed: 15843801]
15. Bober E, Franz T, Arnold HH, Gruss P, Tremblay P. Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. Development (Cambridge, England). 1994; 120:603–612.
16. Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. The EMBO journal. 1991; 10:1135–1147. [PubMed: 2022185]

17. Fan CM, Tessier-Lavigne M. Patterning of mammalian somites by surface ectoderm and notochord: evidence for sclerotome induction by a hedgehog homolog. *Cell*. 1994; 79:1175–1186. [PubMed: 8001153]
18. Schienda J, et al. Somitic origin of limb muscle satellite and side population cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2006; 103:945–950. [PubMed: 16418263]
19. Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. *Biochemical and biophysical research communications*. 1997; 237:752–757. [PubMed: 9299439]
20. Lepper C, Fan CM. Inducible lineage tracing of Pax7-descendant cells reveals embryonic origin of adult satellite cells. *Genesis*. 2010; 48:424–436.10.1002/dvg.20630 [PubMed: 20641127]
21. Buckingham M. Skeletal muscle development and the role of the myogenic regulatory factors. *Biochem Soc Trans*. 1996; 24:506–509. [PubMed: 8736793]
22. Buckingham M, et al. The formation of skeletal muscle: from somite to limb. *J Anat*. 2003; 202:59–68. [PubMed: 12587921]
23. Lassar AB, Paterson BM, Weintraub H. Transfection of a DNA locus that mediates the conversion of 10T1/2 fibroblasts to myoblasts. *Cell*. 1986; 47:649–656.0092-8674(86)90507-6 [PubMed: 2430720]
24. Olson EN. MyoD family: a paradigm for development? *Genes & development*. 1990; 4:1454–1461. [PubMed: 2253873]
25. Kaul A, Koster M, Neuhaus H, Braun T. Myf-5 revisited: loss of early myotome formation does not lead to a rib phenotype in homozygous Myf-5 mutant mice. *Cell*. 2000; 102:17–19.S0092-8674(00)00006-4 [PubMed: 10929709]
26. Rudnicki MA, Braun T, Hinuma S, Jaenisch R. Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. *Cell*. 1992; 71:383–390.0092-8674(92)90508-A [PubMed: 1330322]
27. Yoon JK, Olson EN, Arnold HH, Wold BJ. Different MRF4 knockout alleles differentially disrupt Myf-5 expression: cis-regulatory interactions at the MRF4/Myf-5 locus. *Developmental biology*. 1997; 188:349–362.S0012-1606(97)98670-X10.1006/dbio.1997.8670 [PubMed: 9268580]
28. Kassam-Duchossoy L, et al. Mrf4 determines skeletal muscle identity in Myf5:MyoD double-mutant mice. *Nature*. 2004; 431:466–471.10.1038/nature02876nature02876 [PubMed: 15386014]
29. Hasty P, et al. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. *Nature*. 1993; 364:501–506.10.1038/364501a0 [PubMed: 8393145]
30. Valdez MR, Richardson JA, Klein WH, Olson EN. Failure of Myf5 to support myogenic differentiation without myogenin, MyoD, and MRF4. *Developmental biology*. 2000; 219:287–298. [PubMed: 10694423]
31. Seale P, et al. PRDM16 controls a brown fat/skeletal muscle switch. *Nature*. 2008; 454:961–967.nature0718210.1038/nature07182 [PubMed: 18719582]
32. Kuang S, Kuroda K, Le Grand F, Rudnicki MA. Asymmetric self-renewal and commitment of satellite stem cells in muscle. *Cell*. 2007; 129:999–1010. [PubMed: 17540178]
33. Gensch N, Borchardt T, Schneider A, Riethmacher D, Braun T. Different autonomous myogenic cell populations revealed by ablation of Myf5-expressing cells during mouse embryogenesis. *Development (Cambridge, England)*. 2008; 135:1597–1604.
34. Kanisicak O, Mendez JJ, Yamamoto S, Yamamoto M, Goldhamer DJ. Progenitors of skeletal muscle satellite cells express the muscle determination gene, MyoD. *Developmental biology*. 2009; 332:131–141.S0012-1606(09)00873-210.1016/j.ydbio.2009.05.554 [PubMed: 19464281]
35. Lepper C, Conway SJ, Fan CM. Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements. *Nature*. 2009
36. Montarras D, et al. Direct isolation of satellite cells for skeletal muscle regeneration. *Science (New York, N Y)*. 2005; 309:2064–2067.
37. Mitchell KJ, et al. Identification and characterization of a non-satellite cell muscle resident progenitor during postnatal development. *Nature cell biology*. 2010; 12:257–266.ncb202510.1038/ncb2025

38. Kuang S, Charge SB, Seale P, Huh M, Rudnicki MA. Distinct roles for Pax7 and Pax3 in adult regenerative myogenesis. *The Journal of cell biology*. 2006; 172:103–113. [PubMed: 16391000]
39. Oustanina S, Hause G, Braun T. Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification. *The EMBO journal*. 2004; 23:3430–3439. [PubMed: 15282552]
40. Relaix F, et al. Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. *The Journal of cell biology*. 2006; 172:91–102. [PubMed: 16380438]
41. Studitsky AN. Free Auto- and Homografts of Muscle Tissue in Experiments on Animals. *Ann N Y Acad Sci*. 1964; 120:789–801. [PubMed: 14235292]
42. Luz MA, Marques MJ, Santo Neto H. Impaired regeneration of dystrophin-deficient muscle fibers is caused by exhaustion of myogenic cells. *Braz J Med Biol Res*. 2002; 35:691–695.S0100-879X2002000600009 [PubMed: 12045834]
43. Mauro A. Satellite cell of skeletal muscle fibers. *The Journal of biophysical and biochemical cytology*. 1961; 9:493–495. [PubMed: 13768451]
44. Stockdale FE, Holtzer H. DNA synthesis and myogenesis. *Exp Cell Res*. 1961; 24:508–520. [PubMed: 13917284]
45. Cooper WG, Konigsberg IR. Dynamics of myogenesis in vitro. *The Anatomical record*. 1961; 140:195–205. [PubMed: 14022869]
46. Snow MH. An autoradiographic study of satellite cell differentiation into regenerating myotubes following transplantation of muscles in young rats. *Cell and tissue research*. 1978; 186:535–540. [PubMed: 627031]
47. Seale P, et al. Pax7 is required for the specification of myogenic satellite cells. *Cell*. 2000; 102:777–786. [PubMed: 11030621]
48. Chen Y, Lin G, Slack JM. Control of muscle regeneration in the *Xenopus* tadpole tail by Pax7. *Development (Cambridge, England)*. 2006; 133:2303–2313.dev.0239710.1242/dev.02397
49. Collins CA, et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. *Cell*. 2005; 122:289–301. [PubMed: 16051152]
50. Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM. Self-renewal and expansion of single transplanted muscle stem cells. *Nature*. 2008
51. Cerletti M, et al. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. *Cell*. 2008; 134:37–47. [PubMed: 18614009]
52. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. *Science (New York, N Y)*. 1996; 273:242–245.
53. Peault B, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. *Mol Ther*. 2007; 15:867–877. [PubMed: 17387336]
54. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. *Developmental biology*. 2002; 244:305–318. [PubMed: 11944939]
55. Megency LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA. MyoD is required for myogenic stem cell function in adult skeletal muscle. *Genes & Dev*. 1996; 10:1173–1183. [PubMed: 8675005]
56. Cornelison DD, Olwin BB, Rudnicki MA, Wold BJ. MyoD(-/-) satellite cells in single-fiber culture are differentiation defective and MRF4 deficient. *Developmental biology*. 2000; 224:122–137.10.1006/dbio.2000.9682S0012-1606(00)99682-9 [PubMed: 10926754]
57. Ustanina S, Carvajal J, Rigby P, Braun T. The myogenic factor Myf5 supports efficient skeletal muscle regeneration by enabling transient myoblast amplification. *Stem Cells*. 2007; 25:2006–2016.10.1634/stemcells.2006-0736 [PubMed: 17495111]
58. Gayraud-Morel B, et al. A role for the myogenic determination gene Myf5 in adult regenerative myogenesis. *Developmental biology*. 2007; 312:13–28.10.1016/j.ydbio.2007.08.059 [PubMed: 17961534]
59. Meadows E, Cho JH, Flynn JM, Klein WH. Myogenin regulates a distinct genetic program in adult muscle stem cells. *Developmental biology*. 2008; 322:406–414.S0012-1606(08)01074-9.1016/j.ydbio.2008.07.024 [PubMed: 18721801]

60. Moresi V, et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. *Cell*. 2010; 143:35–45.10.1016/j.cell.2010.09.004 [PubMed: 20887891]
61. Rong PM, Teillet MA, Ziller C, Le Douarin NM. The neural tube/notochord complex is necessary for vertebral but not limb and body wall striated muscle differentiation. *Development (Cambridge, England)*. 1992; 115:657–672.
62. Kuratani S, et al. The expression pattern of the chick homeobox gene *gMHox* suggests a role in patterning of the limbs and face and in compartmentalization of somites. *Developmental biology*. 1994; 161:357–369.10.1006/dbio.1994.1037S0012-1606(84)71037-2 [PubMed: 7906232]
63. Cossu G, et al. Activation of different myogenic pathways: *myf-5* is induced by the neural tube and *MyoD* by the dorsal ectoderm in mouse paraxial mesoderm. *Development (Cambridge, England)*. 1996; 122:429–437.
64. Fan CM, Lee CS, Tessier-Lavigne M. A role for WNT proteins in induction of dermomyotome. *Developmental biology*. 1997; 191:160–165. [PubMed: 9356179]
65. Tajbakhsh S, et al. Differential activation of *Myf5* and *MyoD* by different Wnts in explants of mouse paraxial mesoderm and the later activation of myogenesis in the absence of *Myf5*. *Development (Cambridge, England)*. 1998; 125:4155–4162.
66. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. *Nature*. 2005; 433:317–322.nature0312610.1038/nature03126 [PubMed: 15568017]
67. Ikeya M, Takada S. Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. *Development (Cambridge, England)*. 1998; 125:4969–4976.
68. Brunelli S, Relaix F, Baesso S, Buckingham M, Cossu G. Beta catenin-independent activation of *MyoD* in presomitic mesoderm requires PKC and depends on Pax3 transcriptional activity. *Developmental biology*. 2007; 304:604–614.S0012-1606(07)00020-610.1016/j.ydbio.2007.01.006 [PubMed: 17275805]
69. Dunty WC Jr, et al. Wnt3a/beta-catenin signaling controls posterior body development by coordinating mesoderm formation and segmentation. *Development (Cambridge, England)*. 2008; 135:85–94.dev.00926610.1242/dev.009266
70. Hutcheson DA, Zhao J, Merrell A, Haldar M, Kardon G. Embryonic and fetal limb myogenic cells are derived from developmentally distinct progenitors and have different requirements for beta-catenin. *Genes & development*. 2009; 23:997–1013.gad.176900910.1101/gad.1769009 [PubMed: 19346403]
71. Brack AS, et al. BCL9 is an essential component of canonical Wnt signaling that mediates the differentiation of myogenic progenitors during muscle regeneration. *Developmental biology*. 2009; 335:93–105.S0012-1606(09)01137-310.1016/j.ydbio.2009.08.014 [PubMed: 19699733]
72. Poleskaya A, Seale P, Rudnicki MA. Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. *Cell*. 2003; 113:841–852.S0092867403004379 [PubMed: 12837243]
73. Zhao P, Hoffman EP. Embryonic myogenesis pathways in muscle regeneration. *Developmental dynamics : an official publication of the American Association of Anatomists*. 2004; 229:380–392.10.1002/dvdy.10457 [PubMed: 14745964]
74. Floss T, Arnold HH, Braun T. A role for FGF-6 in skeletal muscle regeneration. *Genes & development*. 1997; 11:2040–2051. [PubMed: 9284044]
75. Zhao P, et al. *Fgfr4* is required for effective muscle regeneration in vivo. Delineation of a *MyoD*-*Tead2*-*Fgfr4* transcriptional pathway. *The Journal of biological chemistry*. 2006; 281:429–438.10.1074/jbc.M507440200 [PubMed: 16267055]
76. Le Grand F, Jones AE, Seale V, Scime A, Rudnicki MA. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. *Cell stem cell*. 2009; 4:535–547.S1934-5909(09)00148-910.1016/j.stem.2009.03.013 [PubMed: 19497282]
77. Otto A, et al. Canonical Wnt signalling induces satellite-cell proliferation during adult skeletal muscle regeneration. *Journal of cell science*. 2008; 121:2939–2950.jcs.02653410.1242/jcs.026534 [PubMed: 18697834]
78. Brack AS, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. *Science (New York, N Y)*. 2007; 317:807–810.

79. Pansters NA, et al. Segregation of myoblast fusion and muscle-specific gene expression by distinct ligand-dependent inactivation of GSK-3beta. *Cell Mol Life Sci.* 2011; 68:523–535.10.1007/s00018-010-0467-7 [PubMed: 20694829]
80. Conboy IM, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature.* 2005; 433:760–764.nature0326010.1038/nature03260 [PubMed: 15716955]
81. Carlson ME, Hsu M, Conboy IM. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. *Nature.* 2008; 454:528–532.nature0703410.1038/nature07034 [PubMed: 18552838]
82. Carlson ME, et al. Relative roles of TGF-beta1 and Wnt in the systemic regulation and aging of satellite cell responses. *Aging Cell.* 2009; 8:676–689.ACE51710.1111/j.1474-9726.2009.00517.x [PubMed: 19732043]
83. Schuster-Gossler K, Cordes R, Gossler A. Premature myogenic differentiation and depletion of progenitor cells cause severe muscle hypotrophy in Delta1 mutants. *Proceedings of the National Academy of Sciences of the United States of America.* 2007; 104:537–542.060828110410.1073/pnas.0608281104 [PubMed: 17194759]
84. Vasyutina E, et al. RBP-J (Rbpsi) is essential to maintain muscle progenitor cells and to generate satellite cells. *Proceedings of the National Academy of Sciences of the United States of America.* 2007; 104:4443–4448.061064710410.1073/pnas.0610647104 [PubMed: 17360543]
85. Spana EP, Doe CQ. Numb antagonizes Notch signaling to specify sibling neuron cell fates. *Neuron.* 1996; 17:21–26.S0896-6273(00)80277-9 [PubMed: 8755475]
86. Jory A, et al. Numb promotes an increase in skeletal muscle progenitor cells in the embryonic somite. *Stem Cells.* 2009; 27:2769–2780.10.1002/stem.220 [PubMed: 19785007]
87. Conboy IM, Rando TA. The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. *Dev Cell.* 2002; 3:397–409.S153458070200254X [PubMed: 12361602]
88. Shinin V, Gayraud-Morel B, Gomès D, Tajbakhsh S. Asymmetric division and cosegregation of template DNA strands in adult muscle satellite cells. *Nature cell biology.* 2006; 8:677–687.
89. Kitamoto T, Hanaoka K. Notch3 null mutation in mice causes muscle hyperplasia by repetitive muscle regeneration. *Stem Cells.* 2010; 28:2205–2216.10.1002/stem.547 [PubMed: 20960513]
90. Meadows E, Flynn JM, Klein WH. Myogenin regulates exercise capacity but is dispensable for skeletal muscle regeneration in adult mdx mice. *PLoS One.* 2011; 6:e16184.10.1371/journal.pone.0016184 [PubMed: 21264243]




Figure 1. Developmental progression of myogenesis and myogenic gene expression

Top panel: presomitic mesoderm cells express *Pax3* (pale blue) and low levels of *Myf5* (pale yellow) transcripts. Epithelial somite stage is omitted. Second panel: appearance of sclerotome, dermomyotome (*Pax3*⁺), and primary (1°) myogenic cells (*Myf5*⁺) at the dorsal medial edge. *Pax3* expression is at a higher level at the lateral edge. Third panel: *Pax7* expression emerges and overlaps with *Pax3*⁺ cells in the central dermomyotome in more mature somites. Bottom panel: Vertical division of the central dermomyotomal cells, which give rise to the secondary (2°) myogenic progenitors. These cells are presumed to give rise to more progenitors and *Myf5*⁺ or *MyoD*⁺ myogenic cells. The lateral *Pax3*⁺ cells give rise to migrating myoblasts entering the ventral body wall and limbs. Keys to cells with specific gene expression are at the bottom.




Figure 2. Pax7 expression is detected in satellite cells of the mouse tibialis anterior muscle
 (A) Immuno-EM detection of endogenous Pax7 by a monoclonal antibody (DSHB), followed by a HRP-conjugated goat anti-mouse IgG1 antibody (Molecular Probes) and enzymatic reaction using the DAB substrate (Vecta Lab). The sample was fixed in Zamboni's fixative following the protocol in Chen et al. (2007). (B) TEM of samples from tamoxifen-treated *Pax7-Cre-ER^{T2};LacZ* reporter mice, fixed in 4% paraformaldehyde, reacted with X-gal substrate, following the procedure in Kanisick et al. (2009). Abbreviations: m, muscle fiber, b, basement membrane; ps, plasmalemmal surface; sc, satellite cell. Arrows in (A) indicate reacted DAB deposits in the nucleus, in (B), reacted X-gal precipitates in the cytoplasm. Some X-gal precipitates are often seen next to satellite cells, likely due to substrate diffusion during enzymatic reaction. Scale bar in (B).




Figure 3. Gene expression and signaling regulation during adult muscle regeneration
 CD34⁺Sca1⁺ side population cells can be converted into Pax7⁺ cells via Wnt/β-catenin signaling. Pax7⁺ satellite cells (red) are associated with the myofiber (pale green) with peripheral myonuclei (white). Upon injury, Pax7⁺ cells either go through symmetric division for self-renewal via the Wnt/PCP pathway or asymmetric division to give rise to committed progenitors (Pax7⁺Myf5⁺, orange) involving Dll/Notch signaling. These cells expand (as transit amplifying cells) and express MyoD (yellow). Myf5 is presumed (Myf5 (?)) to be expressed in transit amplifying cells and Pax7⁺MyoD⁺ myoblasts (yellowish green). Myogenin (green) is turned on in differentiated myocytes, which eventually fuse to form the new myofiber (dark green), which has the characteristic of centrally located myonuclei. Wnt/β-catenin can also convert Pax7⁺ cells into fibroblasts. There are at least two steps of muscle regeneration involving FGF signaling: FGF6 affects MyoD⁺ cells, while FGF4R4 affects myofiber number and size. Gene expression for each stage is confined to those covered in the text and does not represent a full list. Wnt, FGF, and Notch pathways that regulate specific steps of myogenic progression are represented by black lines next to the defined steps.

Table 1

Knock-in allele	Cell types labeled	References	Comments
<i>Pax3-Cre</i> <i>M-Cre</i>	Endothelium Trunk and limb muscle Limb satellite cells Side population cells	Hutchenson et al. Shienda et al.	possible Cre activity in presomitic mesoderm
<i>En1-Cre</i> <i>En1-Cre-ER^T</i>	Trunk Muscle Dorsal dermis Brown fat	Atit et al.	no limb muscle labeled
<i>Pax7-Cre-ER^{T2}</i> <i>Pax7-IRES-Cre-ER^T</i>	Trunk Muscle Limb muscle Dorsal Dermis Brown fat Fetal muscle progenitors Adult satellite cells Adult muscles	Lepper and Fan Keller et al.	cell types labeled dependent on timing of tamoxifen administration
<i>Myf5-Cre</i>	Trunk muscle Limb muscle Brown fat Cartilage Endothelium Adult satellite cells*	Seale et al. Kuang et al. Gensch et al.	Cre activity in presomitic mesoderm *also as committed muscle progenitors
<i>MyoD-Cre</i>	Trunk muscle Limb muscle Perinatal satellite cells	Kanisicak et al.	only myogenic cells were characterized
<i>Myogenin-Cre</i>	Trunk Muscle Limb muscle	Gensch et al.	only muscles are labeled